SCHEMBL652059

SCHEMBL652059

O=C(O)CCC(=O)Nc1ncc(C=C2SC(=Nc3cc(Cl)c(Cl)cc3Cl)NC2=O)s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNASEL Q05823 1/20 0.40
DYRK3 O43781 3/20 0.39
PTPN7 P35236 1/20 0.38
DUSP3 P51452 1/20 0.38
PTPN12 Q05209 1/20 0.38
PTPN22 Q9Y2R2 1/20 0.38
HSD11B1 P28845 1/20 0.37
GSK3B P49841 3/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
POLB P06746 2/20 0.36
PTGS2 P35354 1/20 0.36
CSNK1E P49674 1/20 0.35
CLK1 P49759 1/20 0.35
CLK2 P49760 1/20 0.35
CLK3 P49761 1/20 0.35
DYRK1A Q13627 1/20 0.35
DYRK2 Q92630 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
DYRK4 Q9NR20 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651036 1.00 RNASEL (0.40) RNASELDYRK3PTPN7DUSP3PTPN12
SCHEMBL649070 0.91 CDC25A (0.44) RNASELDYRK3PTPN7DUSP3PTPN12
SCHEMBL649071 0.91 CDC25A (0.44) RNASELDYRK3PTPN7DUSP3PTPN12
SCHEMBL650337 0.88 KMT2A (0.50) PTPN7DUSP3PTPN12PTPN22MEN1
SCHEMBL650338 0.88 KMT2A (0.50) PTPN7DUSP3PTPN12PTPN22MEN1
SCHEMBL648560 0.87 CDC25A (0.44) RNASELDYRK3HSD11B1GSK3BMEN1
SCHEMBL649992 0.87 CDC25A (0.44) RNASELDYRK3HSD11B1GSK3BMEN1
SCHEMBL651165 0.84 MAPT (0.52) RNASELMEN1KMT2APOLBPTGS2
SCHEMBL651164 0.84 MAPT (0.52) RNASELMEN1KMT2APOLBPTGS2
SCHEMBL653261 0.84 NPC1 (0.50) DYRK3PTPN7DUSP3PTPN12PTPN22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 RNASEL 4113/4885DYRK3 1808/4885PTPN7 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.